| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 24 May 2024 | 10 May 2024 |
| TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2024 inter alia to consider and approve We would like to inform you that: 1. A meeting of the Board of Directors will be held on Friday 24-May-24 inter alia to consider and approve the Audited Financial Results of the Company for the year ended on 31-Mar-24. 2. In the above meeting the Board would also consider the following: i. Recommendation of final dividend if any on the equity shares of the Company for the year 2023-24. ii. Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes. If approved by the Board of Directors the said item will be placed for Shareholders approval in the ensuing Annual General Meeting. Kindly take note of the above. Outcome of Board meeting dated 24-May-24 Results (As Per BSE Announcement dated on 24.05.2024) | ||
| Board Meeting | 2 Feb 2024 | 12 Jan 2024 |
| TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2024 inter alia to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Friday 02-Feb-24 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on 31-Dec-23. The Board would also consider payment of Interim Dividend for the year 2023-24. Board declared an interim dividend of Rs. 22/- (440%) per equity share of Rs. 5/- fully paid up. The dividend is expected to be paid/ dispatched on or around 23rd February, 2024. The Board of Directors acceded to the desire of Sudhir Mehta to step down as the Director of the Company while continuing as Chairman Emeritus effective from 1st Apr-24. (As Per BSE Bulletin Dated on 02.02.2024) | ||
| Board Meeting | 23 Oct 2023 | 9 Oct 2023 |
| TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2023 inter alia to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Monday 23-Oct-23 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-23. Financial results for quarter and half year ended 30-sep-23 (As per BSE Announcement Dated on 23/10/2023) | ||
| Board Meeting | 7 Aug 2023 | 15 Jul 2023 |
| TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2023 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter ended on 30-Jun-23. TORRENT PHARMACEUTICALS LIMITED has informed BSE about Board Meeting to be held on 07 Aug 2023 to consider financial statements for the period ended June 2023. Financial results. Submission / Intimation u/r 30 of SEBI (LODR) Regulation, 2015 - Financial Result for quarter ended 30th June, 2023 Board has at its meeting held today approved, inter alia, the Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with limited review report of the Company for the quarter ended 30th June, 2023. The said financial results are enclosed herewith. (As Per BSE Announcement Dated on 07.08.2023) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
